Transgene

Beleggen in aandelenbeurzen Europa: DAX, FTSE 100, CAC40, etc.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 728
Lid geworden op: 30 mei 2018 21:25
waarderingen: 307
Contacteer:

Re: Transgene

Bericht door And its gone! »

En freeze, het putje in.
Wachten op Godot dit aandeel.
GOOGL, BAYN, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, BCYC, YMAB, ZYME, GERN, BNTX, SWTX, BPMC, RCUS, TRIL, SPCE.





Volg Beursig.com op Twitter en Facebook

     


Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 728
Lid geworden op: 30 mei 2018 21:25
waarderingen: 307
Contacteer:

Re: Transgene

Bericht door And its gone! »

BRIEF-Vaxxel Acquires Transgene's DuckCelt-T17 Cell Line
08:11 (04/05) - Bron: Reuters
May 4 (Reuters) - TRANSGENE SA TRNG.PA :
* VAXXEL ACQUIRES TRANSGENE'S DUCKCELT®-T17 CELL LINE TO
DEVELOP
INDUSTRIAL-SCALE VACCINES AGAINST RESPIRATORY VIRUSES
* TRANSGENE BECOMES A SHAREHOLDER OF VAXXEL. DUCKCELT®-T17,
INITIALLY DEVELOPED AND PATENTED BY TRANSGENE, IS AN AVIAN CELL
LINE GROWN IN SUSPENSION

Source text for Eikon:
Further company coverage: TRNG.PA

(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
GOOGL, BAYN, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, BCYC, YMAB, ZYME, GERN, BNTX, SWTX, BPMC, RCUS, TRIL, SPCE.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 728
Lid geworden op: 30 mei 2018 21:25
waarderingen: 307
Contacteer:

Re: Transgene

Bericht door And its gone! »

BRIEF-Transgene Q1 Operating Revenue Up At 3.0 Million Euros
17:58 (06/05) - Bron: Reuters
May 6 (Reuters) - TRANSGENE SA TRNG.PA :
* REPORTS Q1 2020 FINANCIAL POSITION AND BUSINESS UPDATE
* IN Q1 OF 2020, TRANSGENE'S CASH BURN WAS EUR 8.0 MILLION,
COMPARED TO EUR 7.8 MILLION FOR SAME PERIOD IN 2019
* MINOR IMPACT FROM THE COVID-19 PANDEMIC SEEN TO-DATE
* EXPECTS ITS CASH BURN FOR 2020 TO BE AROUND EUR 25
MILLION,
BASED ON ITS CURRENT DEVELOPMENT PLAN
* Q1 OPERATING REVENUE EUR 3.0 MILLION VERSUS EUR 2.0
MILLION YEAR
AGO
* EXPECTS LABS TO BE OPERATING AT CLOSE TO NORMAL LEVELS
STARTING
NEXT WEEK

Source text for Eikon:
Further company coverage:

(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
GOOGL, BAYN, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, BCYC, YMAB, ZYME, GERN, BNTX, SWTX, BPMC, RCUS, TRIL, SPCE.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 728
Lid geworden op: 30 mei 2018 21:25
waarderingen: 307
Contacteer:

Re: Transgene

Bericht door And its gone! »

BRIEF-Transgene Says Data Confirms High Accuracy Of Cancer Vaccine TG4050
07:41 (15/05) - Bron: Reuters
May 15 (Reuters) - TRANSGENE SA TRNG.PA :
* TRANSGENE AND NEC DEMONSTRATE HIGH ACCURACY OF AI-BASED
NEOANTIGEN PREDICTION FOR THE DESIGN OF INDIVIDUALIZED CANCER
VACCINE TG4050
* DATA CONFIRM THAT PREDICTION ALGORITHM SUCCESSFULLY
IDENTIFIES
IMMUNOGENIC CANCER MUTATIONS

Source text for Eikon:
Further company coverage:

(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Transgene and NEC demonstrate high accuracy of AI-based
neoantigen prediction for the design
of individualized cancer vaccine TG4050
✓ TG4050 is being evaluated in two Phase 1 clinical trials. It combines Transgene’s
proprietary myvac® platform with NEC’s cutting-edge Artificial Intelligence (AI)
capabilities to select patient-specific neoantigens
✓ Data confirm that the prediction algorithm successfully identifies immunogenic
cancer mutations, even among a large set of candidate mutations
✓ Data will be presented at upcoming Virtual AACR 2020 Session II
Strasbourg, France & Tokyo, Japan, May 15, 2020, 7:30 am CET - Transgene (Euronext Paris: TNG),
a biotech company that designs and develops virus-based immunotherapies for the treatment of
cancer, and NEC Corporation (NEC; TSE: 6701), a leader in IT and network technologies, today
announce that they will present data demonstrating that the prediction algorithm used to
customize TG4050 for each patient is accurate at identifying immunogenic cancer mutations even
among a large set of candidate mutations. These data were jointly generated by the Transgene,
NEC and teams and NEC Laboratories Europe GmbH will be presented at the upcoming meeting
of the American Association for Cancer Research (AACR) Annual Meeting 2020 (AACR Virtual
Annual Meeting II).
TG4050 is an individualized therapeutic vaccine based on Transgene’s myvac® technology. It is
powered by NEC’s cutting-edge AI capabilities. Two Phase 1 trials with TG4050 are ongoing in
Europe and in the USA.
TG4050 has been designed to target up to 30 patient-specific neoantigens (cancer cell mutations)
which are selected using NEC’s Neoantigen Prediction System, an advanced AI technology that has
already been applied in the field of oncology. The prediction system is based on more than two
decades of expertise in AI and has been trained on proprietary immune data, allowing it to
accurately prioritize and select the most immunogenic sequences.
To evaluate the accuracy of the prediction, samples from cancer patients were collected. Healthy and
tumor tissue were sequenced, and mutations were identified and ranked using the algorithm. These
were then evaluated by measuring the frequency of T cells against the predicted antigens. Although
preliminary, the results generated to-date suggest that the system can identify rare immunogenic
mutation among a large list of candidates identified in the patients.
Transgene uses its expertise in viral vectorization to incorporate the selected neoantigen sequences
in the genome of the Modified Vaccinia virus Ankara (MVA) viral vector. The Company has set up a
unique in-house good manufacturing practice (GMP) unit dedicated to manufacturing the
individualized batches of TG4050 needed for the clinical development of this novel individualized
therapeutic vaccine.
Page 2 / 3
• Title of the poster: “Performance of neoantigen prediction for the design of TG4050, a patient
specific neoantigen cancer vaccine”
• Authors: Brandon Malone, Caroline Tosch, Benoit Grellier, Kousuke Onoue, Timo Sztyler,
Karola Rittner, Yoshiko Yamashita, Eric Quéméneur, Kaïdre Bendjama
• Session Date and Time: June 22-24, 2020
• Abstract Number: 4566
The abstract can be downloaded on the AACR website.
mongoose liked last!
GOOGL, BAYN, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, BCYC, YMAB, ZYME, GERN, BNTX, SWTX, BPMC, RCUS, TRIL, SPCE.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 728
Lid geworden op: 30 mei 2018 21:25
waarderingen: 307
Contacteer:

Re: Transgene

Bericht door And its gone! »

Combined General Meeting of May 27, 2020
Strasbourg, France, May 27, 2020, 05:45 p.m. CET – The Combined Ordinary and Extraordinary
General Meeting of Transgene’s shareholders was held today (May 27, 2020) at 10:00 a.m. at the
Company's headquarters (400 boulevard Gonthier d'Andernach - Parc d'Innovation - 67400 IllkirchGraffenstaden) chaired by Philippe Archinard, Chairman and CEO, to approve the company financial
statements for the year ended December 31, 2019 and to vote the others resolutions submitted to
their approval. As a result of restrictions placed on the movement and gatherings of persons in the
context of the COVID-19 pandemic, this General Meeting was held behind closed doors without the
physical presence of its shareholders.
At the Combined General Meeting, the shareholders have:
- renewed the mandates of the following Board Members: Philippe Archinard, Benoît Habert,
Marie Landel, Maya Saïd and TSGH, Transgene’s majority shareholder, represented by Dominique
Takizawa;
- voted the other resolutions submitted, in accordance with the recommendations of the Board
of Directors.
Detailed voting results are available on Transgene's website, under the heading Investors > General
Meeting.
In the board meeting following the Combined General Meeting, the board of directors:
- confirmed Mr Philippe Archinard, Mrs Marie Landel and Mr Benoît Habert in their respective
mandates as Chairman of the Board, Chairman of the Audit Committee and Chairman of the
Compensation Committee;
- implemented the reduction of the nominal value from 1.00 euro to 0.50 euro per share.
GOOGL, BAYN, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, BCYC, YMAB, ZYME, GERN, BNTX, SWTX, BPMC, RCUS, TRIL, SPCE.

BRT
Forum actieveling
Forum actieveling
Berichten: 307
Lid geworden op: 14 sep 2018 11:22
waarderingen: 90
Contacteer:

Re: Transgene

Bericht door BRT »

Ben eens benieuwd naar fase 2 TG4001, therapeutisch vaccin. Data wordt verwacht in Q2 2020. Als dit ook faalt, is de pipeline dood als een pier.

Blijft nog steeds boeiend pionierswerk.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 728
Lid geworden op: 30 mei 2018 21:25
waarderingen: 307
Contacteer:

Re: Transgene

Bericht door And its gone! »

BRT schreef:
06 jun 2020 15:58
Ben eens benieuwd naar fase 2 TG4001, therapeutisch vaccin. Data wordt verwacht in Q2 2020. Als dit ook faalt, is de pipeline dood als een pier.

Blijft nog steeds boeiend pionierswerk.
Results moeten deze week vallen.
Te hopen dat ze goed zijn want dit is de zwaarste verlies post in porto met een rendement van net geen -50% :D
GOOGL, BAYN, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, BCYC, YMAB, ZYME, GERN, BNTX, SWTX, BPMC, RCUS, TRIL, SPCE.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 728
Lid geworden op: 30 mei 2018 21:25
waarderingen: 307
Contacteer:

Re: Transgene

Bericht door And its gone! »

BRIEF-Transgene: New Data From Next-Generation Immunotherapy Platforms
15:29 (22/06) - Bron: Reuters
June 22 (Reuters) - Transgene SA TRNG.PA :
* TRANSGENE PRESENTS PROMISING NEW DATA FROM ITS
NEXT-GENERATION
IMMUNOTHERAPY PLATFORMS AT AACR 2020
* DATA DEMONSTRATING THAT PREDICTION ALGORITHM USED TO
CUSTOMIZE
TG4050 FOR EACH PATIENT IS ACCURATE AT IDENTIFYING IMMUNOGENIC
CANCER MUTATIONS EVEN AMONG A LARGE SET OF CANDIDATE TUMOR
MUTATIONS
* RESULTS DEMONSTRATE THAT SPECIFICITY OF OUR APPROACH
OUTPERFORMS
INDUSTRY STANDARD AND ARE EXPECTED TO TRANSLATE IN ENHANCED
ACTIVITY IN PATIENTS

Source text for Eikon:
Further company coverage:

(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
GOOGL, BAYN, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, BCYC, YMAB, ZYME, GERN, BNTX, SWTX, BPMC, RCUS, TRIL, SPCE.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 728
Lid geworden op: 30 mei 2018 21:25
waarderingen: 307
Contacteer:

Re: Transgene

Bericht door And its gone! »

BRIEF-Transgene’s, Bioinvent’s BT-001 Achieves High Tumor Cure Rates In Preclinical Models
15:33 (22/06) - Bron: Reuters
June 22 (Reuters) - Transgene SA TRNG.PA :
* TRANSGENE’S AND BIOINVENT’S BT-001 ACHIEVES OUTSTANDING
TUMOR
CURE RATES IN PRECLINICAL MODELS
* PROOF OF CONCEPT FOR NOVEL ONCOLYTIC VIRUS WITH
DIFFERENTIATED
ANTI-CTLA4 ANTIBODY
* SIGNIFICANT ANTITUMOR ACTIVITY OF BT-001 SEEN IN SEVERAL
IMMUNOCOMPETENT MODELS
* TREATMENT WITH BT-001 ALSO INDUCED A SPECIFIC AND
LONG-LASTING
IMMUNE MEMORY, WHICH IS THOUGHT TO ACT ON DISTANT TUMORS AND TO
PREVENT POTENTIAL RELAPSE
* PHASE I CLINICAL TRIAL WITH BT-001 EXPECTED TO START
BEFORE END
OF 2020

Source text for Eikon:
Further company coverage:

(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
NewB76 liked last!
GOOGL, BAYN, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, BCYC, YMAB, ZYME, GERN, BNTX, SWTX, BPMC, RCUS, TRIL, SPCE.

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 728
Lid geworden op: 30 mei 2018 21:25
waarderingen: 307
Contacteer:

Re: Transgene

Bericht door And its gone! »

BRT schreef:
06 jun 2020 15:58
Ben eens benieuwd naar fase 2 TG4001, therapeutisch vaccin. Data wordt verwacht in Q2 2020. Als dit ook faalt, is de pipeline dood als een pier.

Blijft nog steeds boeiend pionierswerk.
Nog steeds geen pb van Transgene.

-Kort geleden Pb's gehad van de meer prille projecten in de pipeline;
-Wacht tot de laatste dag van maand om hun results van TG4001 vrij te geven;

Doen mij vermoeden dat het weer een teleurstelling zal zijn, dat is dan de 3de keer sinds ik aandeelhouder ben. :D

Hoop dat ik verkeerd ben.
GOOGL, BAYN, TNG, ALPHA, IPH, RDSA, IVA, VYGR, HARP, BCYC, YMAB, ZYME, GERN, BNTX, SWTX, BPMC, RCUS, TRIL, SPCE.

Deelnemen aan het forum + meer functies?

Discussieer met duizenden beleggers, minder
advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen. Registreer binnen 1 minuut!


Plaats reactie